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C-reactive protein (CRP) 1 is an acute-phase protein in man that is of considerable 
interest, in part because serum concentrations increase from  20- to several hundred- 
fold  during  inflammation  or  acute  tissue  injury  (1,  2).  The  association of elevated 
levels of CRP with activation of certain immune responses led to the postulation that 
CRP  is  involved  in  initiation  or  regulation  of  lymphocyte  function  (3).  Recent 
evidence of similarities between  CRP-binding cells and  the effector cell responsible 
for natural killer (NK)  cell-mediated lysis prompted our investigation of the role of 
CRP in the NK response. NK and CRP-binding cells are large granular lymphocytes 
(LGL), bear IgG Fc receptors, represent only a  small percentage of the total lympho- 
cyte population, and rosette similarly with sheep erythrocytes (4-8). 
These experiments were initiated to determine whether NK cells bear CRP, whether 
cell-bound CRP  is involved in the effector phase of the NK  response,  and whether 
CRP  or CRP-complex binding would  alter NK  function  (9-12),  that  is, they were 
designed  to  examine  whether  CRP  or  CRP  complexes  are  involved  in  NK  cell- 
mediated killing. The results demonstrate that CRP is present on at least certain NK 
effectors, that CRP or a  molecule that co-caps with CRP  is required for optimal NK 
function,  and  that  cell-surface CRP  and  not  fluid-phase  CRP  is  involved  in  the 
mediation of NK activity. 
Materials  and  Methods 
Purification  and  Characterization of CRP and  CPS.  CRP  was  prepared  from  pooled human 
serous fluids by phosphocholine-affinity, DE-52, and Sephacryl S-200 (Pharmacia Fine Chem- 
icals, Div. of Pharmacia Inc., Piscataway, N  J) column chromatography by methods previously 
described  (13).  CRP  preparations were  concentrated by ultrafiltration, sterile filtered, and 
stored at 4°C. When examined by reduced sodium dodecyl sulfate-polyacrylamide gel electro- 
phoresis (14),  purified CRP  produced a  single band corresponding to CRP  subunits with a 
molecular weight of 21,500  +  500.  A  single peak of 1251 was obtained after sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis analysis of labeled CRP  (15).  Purified CRP  was 
concentrated to  10 mg/ml by ultrafiltration and no IgG, IgA, IgM, C3, or serum amyloid P 
component were detected using radial immunodiffusion plates with limits of sensitivity of 5/zg/ 
ml. Ouchterlony analysis of the concentrated material revealed a single precipitation line with 
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anti-CRP and no reactivity with anti-whole human serum~ Heat-modified CRP (H-CRP) was 
prepared  by heating purified CRP for 2 min at 63°C.  Pneumococcal C-polysaccharide (CPS) 
was obtained by the methods of Liu and Gotschlich (16)  as previously modified  (13). 
Anti-CRP.  Initial  experiments  were  performed  with  the  IgG  fraction  of goat  anti-CRP 
prepared  and  characterized  as  previously  described  (13).  Characterization  of this  antibody 
involved both  Ouchterlony  diffusion  analysis  and  passive  hemagglutination  using  antigens 
coupled  to erythrocytes by chromium chloride.  No antibody  activity against  IgG, C3, serum 
amyloid P component, CPS, or antigens contained in normal human serum was detectable. In 
other experiments we used sheep anti-CRP (N. L. Cappel Laboratories,  Cochranville, PA) or 
goat  anti-CRP  that  had  been  affinity purified  by passage  over CRP-Sepharose  (Pharmacia 
Fine Chemicals)  (12).  Before dilution, the concentration of the affinity-purified antibody was 
1 mg/ml. Similar results were obtained in all cases. All antisera were extensively dialyzed into 
media immediately before use. 
Lymphocyte Preparation.  Lymphocytes were obtained  from  heparinized  peripheral  blood of 
norma}  individuals  and  were separated  on  lymphocyte-separation  medium  (17).  Cells were 
collected in sodium  heparin  (20  U/ml)  or EDTA  (I  mg/ml).  Peripheral  blood  lymphocytes 
(PBL) were then washed and resuspended in RPMI  1640 medium containing 0.05% gelatin. In 
some experiments, a subpopulation  of cells was removed by adherence to tissue culture dishes. 
Normal donors were tested for NK levels; optimal responder cell numbers ranged from 5 X  10  4 
to 2 X  10  s per 0.2 ml culture. 
Enrichment of LGL.  Human  PBL were enriched  for NK activity by Percoll-gradient  sepa- 
ration by the modified methods ofTimonen et al. (5, 6, 18). Before density-gradient separation, 
phagocytic cells were removed: after incubation  in RPMI  medium containing 25%  fetal calf 
serum  and  10 mg/ml of carbonyl  iron  and  rotation  at  37°C  for 30 min,  they were removed 
with  a  pencil  magnet.  The  remaining  lymphocytes  were  gently layered  on  a  discontinuous 
gradient  composed  of  five  2.5-ml  layers  of  Percoll  (Pharmacia  Fine  Chemicals,  Div.  of 
Pharmacia  Inc.)  in  RPMI ranging  from 34 to 50%  Percoll. No more than  5  X  107 cells were 
layered onto a ~ingle gradient. Cells were centrifuged at 550 g foE"  30 min at room temperature. 
Each  layer of lymphocytes was removed from the gradient, resuspended  in RPMI containing 
10%  fetal  calf serum,  washed,  and  counted.  The  exact  percentage  of lymphocytes  obtained 
from  each  layer  varied  with  the  donor.  Depending  upon  the  percentage  of  lymphocytes 
recovered in the top two layers of the gradient, cells from these fractions were either pooled or 
examined separately.  By this technique the LGL content  of the phagocyte-depleted  mononu- 
clear cell preparation was enriched 5- to 10-fold. These enriched cells were incubated for 1 h at 
37°C in a  humidified 5% COz environment with a  t: 100 dilution of OKT3 antibody  (Ortho 
Pharmaceutical Corp., Raritan, N  J), washed, and resuspended in a  1:10 dilution of baby rabbit 
complement  (C) for 45 min. The remaining lymphocytes will be referred to as phagocyte- and 
T  lymphocyte-depicted LGL. 
Anti-CRP and C Pretreatments.  PBL, phagocyte- and T  lymphocyte-depleted LGL, or target 
cells were brought  to a  concentration  no greater than  1 ×  10  v cells/ml in RPMI containing 
10% fetal calf serum.  Cells were incubated  for 30 rain at 37°C in the presence or absence of a 
I:8 dilution of anti-CRP,  washed, and  resuspended  in a  I: 10 dilution of C  for 30-45  min at 
37°C.  After incubation  with  antibody  and  C,  cells  again  were  washed  and  resuspended  to 
appropriate cell concentrations in the presence of SICr-labeled target cells. 
K562 Target Cells.  The K562  myeloid cell line was maintained  in RPMI  medium supple- 
mented  with  10%  fetal  calf serum,  2  mM  glutamine,  and  1%  penicillin-streptomycin.  They 
were  passed  twice a  week by  resuspension  to  a  concentration  of 2.5  ×  l0 s cells/ml  in  fresh 
medium.  K562  cells to be used  as  target  cells were labeled with 51Cr by incubating  5  ×  106 
cells/rot in  RPMI containing  100 ~Ci of SlCr at  37°C for  i  h.  After labeling, the cells were 
washed three to five times in RPMI containing 0.05% gelatin and resuspended  in this medium 
before use. 
51Cr-Release Assay.  A  4-h SlCr-release assay using 5  x  l0  s effector cells and 5  ×  103 or  1 × 
104 51Cr-labeled K562 was performed. For this assay, cells were incubated in RPMI containing 
0.05% gelatin in 0.2-ml microtiter wells at 37°C in a humidified 5% CO2 atmosphere.  Half (100 
#1) of the culture supernatant  fluid was then harvested with a micropipet (Eppendorf; Brinkman 
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controls  were  considered  acceptable  only  if spontaneous  release  was  <15%  of the  detergent 
release value. The formula used for calculation of the percent specific release (% SR)  was 
% SR  ~  experimental release -  spontaneous release ×  100. 
detergent release -  spontaneous release 
S-CRP and Analysis of Capping.  Cells from normal donors were incubated  with biotinylated 
(19)  affinity-purified  goat  anti-human  CRP  (12)  for  30  rain  at  4°C,  washed,  and  incubated 
with fluorescent avidin (E-Y Laboratories, San Mateo, CA) for 30 rain at 4°C, and resuspended 
to  107 cells/ml. Aliquots of cells (200/~1)  were then incubated  at 37°C for various times before 
fixation  with  an  equal  volume  of  2%  paraformaldehyde,  washed  twice,  and  analyzed  for 
capping according to criteria established by Schreiner and Unanue  (20). 
Results 
Treatment of PBL with Anti-CRP and C Results in a Loss of  Functional NK Activity.  When 
human lymphocytes were sequentially treated with anti-CRP and C  and assayed for 
NK activity, their ability to kill K562 target cells was substantially depleted.  Three 
representative experiments are presented in Table I. In these experiments functional 
activity was  totally eliminated  at  a  concentration  of 1 X  l0  s cells per culture  and 
substantially depleted at higher cell concentrations. Although NK function could be 
depleted,  anti-CRP  and  C  did  not  remove enough  cells  for loss  of viability  to  be 
detectable by trypan blue exclusion. Comparable concentrations of F(ab')2 anti-CRP 
(21) and anti-IgG (22) were used as control antibodies. Treatment with either of these 
antibodies and C, or with C  alone, did not alter the NK response (Table I). Similar 
results  were  obtained  when  anti-CRP  that  had  been  eluted  from a  CRP  affinity 
column was used.  When  PBL were depleted  of adherent cells before treatment with 
antibody and C, the pattern of results was not altered, as seen in Table I, experiment 
3. In most experiments, the concentration ofanti-CRP used for C-mediated depletion 
of effector cells alone (1:8 dilution)  had no effect on NK activity. These experiments 
indicate that CRP or an antigenically similar molecule is found on at least some of 
the PBL that mediate the natural killer cell response. 
TABLE  I 
Treatment of Effectors with Anti-CRP and Complement Removes NK Activity 
Antibody*  Complement§ 
Percent specific 51Cr release 
Experiment  1  Experiment 2  Experiment 3* 
Effector ceil number 
2×  I05  I X  105  2×  105  1 ×  105  4X  l0  s  l  ×  l0  s 
WholeaCRP  +  9_+  lJJ  0±0  11 ±  11  0+  1  9+3  0±  1 
F(ab')2 aCRP  +  --  --  37 ±  9  11 ±  4  32 ±  3  4 +  1 
Whole aIgG  +  28 ±  1  19 ±  1  .... 
None  +  26±3  16-  1  39±  10  16±  10  34±  1  7±  1 
None  -  31  :t: 2  21  ±  2  45 ±  7  15 _+ 3  31 --4--  6  5 +  1 
* Adherent cells were removed by adherence to tissue culture dishes in certain experiments, e.g., experiment 
3. 
:~ PBL were separated on LSM and incubated with a  1:8 dilution ofanti-CRP for 30 rain at 37°(3. 
§ Cells were washed and incubated with a  1:16 dilution of rabbit  complement for 45 rain at 37°C, then 
washed again before a  4-h incubation with 5  X  10  a SlCr-labeled  K562 targets. Cells not treated  with 
antibody and/or complement were comparably incubated and washed. 
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Anti-CRP and  C  Treatment of Phagocyte- and  T  Lymphocyte-depleted LGL  Lowers NK 
Response.  Phagocytic cells were removed from the PBL with a magnet after carbonyl 
iron ingestion. The remaining cells were enriched for LGL by discontinuous Percotl- 
gradient  separation  and  were  treated  with  OKT3 monoclonal antibody and  C  to 
remove  T  lymphocytes. These  phagocyte- and  T  lymphocyte-depleted  LGL were 
incubated in the presence or absence of anti-CRP before C was added. The groups of 
cells  incubated in the presence of anti-CRP demonstrated a  substantially lower NK 
response than those incubated in the absence of anti-CRP, which indicates that  the 
effector cell mediating an NK response has CRP antigenicity present  on its  surface 
(Fig.  1). 
Pretreatment of PBL with High  Concentrations of Anti-CRP Inhibits  ArK Response in  the 
Absence of C.  Incubation of PBL in the presence of a  1:8 dilution of anti-CRP and no 
C occasionally resulted in loss of functional activity. This prompted us to look at the 
effects of various dilutions of antibody alone on the NK response. The results (Fig.  2) 
indicate  that  preincubation  of  effectors  with  a  twofold  higher  (1:4  or  greater) 
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Fro.  h  Anti-CRP and C treatment is effective  in removal of NK activity from phagocyte- and T 
cell-depleted LGL. Mononuclear cells were separated from peripheral blood, phagocytic cells were 
removed  by  carbonyl  iron  ingestion,  LGL  were  purified  on  a  Percoll  gradient,  and  OKT3  + 
lymphocytes were removed by treatment with OKT3 antibody and C. These enriched  NK cells 
were then treated with anti-CRP and C  ((9) or with C  alone (0)- Each point represents the mean 
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Fno.  2,  Pretreatment with high concentrations of anti-CRP  can  inhibit  an  NK response in  the 
absence of complement. Mononuclear cells  were separated  from peripheral blood and  incubated 
with various dilutions of anti-CRP.  Labeled K562 target cells  then were added, and ~XCr released 
was measured. The shaded area of the figure represents the mean and  1 SD of the NK response in 
the absence of anti-CRP. Each point is the mean ±  SD of values obtained from four to six replicate 
cultures. 
concentration of anti-CRP alone greatly reduces functional NK activity. When cells 
were incubated  with Fab fragments of anti-CRP,  there was no loss of NK activity, 
and  inclusion  of anti-CRP  with  no  preincubation  period  did  not  inhibit  the  NK 
response  (unpublished  observations).  When  the  effects of similar concentrations  of 
anti-IgG antiserum were examined, no inhibition  of the NK response was observed 
(Table II). 
Binding Studies Reveal the Presence of Surface CRP (S-CRP) and Capping of S-CRP on 
PBL.  Studies that demonstrated the presence of a small percentage of cells that bind 
complexed CRP initially failed to reveal a population of lymphocytes with detectable 
CRP on their surface (13,  15). The ability ofanti-CRP and C  to deplete NK activity 
prompted  us  to  look for lymphocyte S-CRP  by biotin-avidin  amplification.  Using 
this  sensitive  detection  system,  we  enumerated  cells  bearing  S-CRP  in  peripheral 
blood  and  found  them  in  percentages  that  were  similar  to  those  of cells  binding 
complexed CRP  (Table III). We examined  the ceils that  interact with  biotinylated 
anti-CRP  and  fluorescent  avidin  to  determine  whether  this  interaction  initiated 
capping. S-CRP redistributed to a polar cap in all positive lymphocytes by 8 min at 306  C-REACTIVE  PROTEIN  IN  THE  NATURAL  KILLER  RESPONSE 
TABCE  II 
Preincubation  with Anti-CRP Inhibits an NK Response 
Correlation  % SR at 20:1 
Preincubation*  Lyric units:}:  coefficient§  (E/T)[  I 
RPMI  13.6  0.996  22 
Anti-CRP  3.1  0.938  5 
Anti-IgG  13.9  0.996  22 
* Cells were incubated  with RPMI,  a  I:4 dilution  of anti-CRP,  or Anti-IgG  for 30 
min at 37°C, washed, and resuspended in RPMI containing  1% gelatin  for 30 rain 
before 51Cr-labeled  K562 target cells were added. 
Expressed as mean lytic units at a  33% level/106 cells. 
§ Measure of linearity of four experimental points. 
I] Effector/target. 
TABLE  III 
S-CRP is Detectable  on PBL 
Percent of 
CRP-  FITC anti-  B anti-CRP  Percent positive  Range  positive 
CPS*  CRP  FI avidin  cells  cells that 
cap1: 
--  +  -  0.4 +_. 0,6§  0.0-1.4  -- 
+  +  -  3.5 +  0.6  0.3-8.7  100 
-  -  +  3.9 +  0.8  0.5-12.0  100 
* Cells were incubated in the presence of CRP-CPS complexes before assay. 
:~ Percent of positive cells that cap at  15 min at 37°C. 
§ Mean -- SE of values obtained from 16 individuals. 
TABLE  IV 
Effects of CRP or CRP-CPS Complexes  on NK Response 
Culture additions* 
Percent specific ~ICr release 
Effector cetl number 
Experiment  1  Experiment  2:~  Experiment  3 
3×  l05  1 ×  l0 s  3X  105  2×  10  s  1 ×  105 
RPMI  52 +  4§  34 +  3  23  +  3  23 _+ 5  9  ±  3 
CRP  (50 ~g/ml)  47 ±  9  27 +  3 
(100 ,ug/ml)  44±  13  27+9  20+2  19+4  7±2 
(200/Lg/ml)  42 +_  10  27 +  1 
CPS  (5/~g/ml)  21  +  1  17 ±  0  4 +  3 
CRP-CPS  (20:1)1 [  20 +- 3  20 +  3  10 ±  1 
(50:1)  23 +__ 2 
(100:1)  47 +  5  23 ±  6  23 +__ 1  16 +  4  8 +  3 
* PBL effector cells were incubated with 5 X  103 aCr-labeled  K562  target cells in RPMI and <10 
/d of CRP, CPS, or CRP-CPS. 
:~ Macrophages were removed by adherence to plastic in experiments 2 and 3 but not in  1. 
§ Mean ±  SD. 
II Appropriate ratios of CRP-CPS were obtained by using 100/~g/ml CRP and 5, 0.2, or 1/tg/ml of 
CPS, respectively. BAUM, JAMES,  GLAVIANO, AND  GEWURZ 
TABLE  V 
Heat-modified CRP Does Not Alter NK Response to K562 Targets 
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Culture additions* 
Percent specific 51Cr release 
Effector cell number 
Experiment 1  Experiment 2 
2X 105  1 ×  105  3×  105 
Buffer only  29 ±  3:~  15 ±  1  9 ±  l 
50/xg/ml CRP  31 ± 4  12 -.+- 4  9 ± 0 
50 #g/ml H-CRP  30 ±  2  15 ±  3  8 ± 0 
Buffer only  30±  I  15 +  1  8+  1 
100#g/ml CRP  29 +  1  13 ±  2  7 ±  1 
100 #g/ml H-CRP  26 ±  3  14 :iT 0  7 ± 0 
Buffer only  25 ±  2  8 ±  1  7 ±  5 
200 #g/ml CRP  26 ± 6  10 ±  2  3 + 0 
200 #g/ml H-CRP  21  ±  1  8 ±  1  3 ±  1 
* PBL were incubated with K562  target cells and various 
CRP, or H-CRP. 
:[: Mean +  SD. 
concentrations of buffer, 
TABLE  VI 
K562 Target Cells Are Not Killed by ]treatment with Anti-CRP and Complement 
Comple- 
Preincubation*  Antibody~  ment§ 
Percent of cells recovered 
after treatment 
Experiment 1  Experiment 2 
None 
CRP 
CRP-CPS 
-  -  100  72 
-  +  80  66 
+  +  100  66 
-  -  90  68 
+  +  100  84 
-  -  86  NDll 
+  +  100  ND 
* 5  ×  106  K562  target  cells  were  preineubated with  buffer,  CRP,  or  CRP-CPS 
complexes for 30 min at 37°C. 
:~ Target cells were treated with anti-CRP at 37°C for 30 mln. 
§ Cells were washed, treated with complement for 45 rain, washed again, and counted 
for viability in the presence of trypan blue. Viabilities were always within 1% in any 
experiment. More than 200 ceils were counted in every case. 
[[ Not done. 
37°C and capped  off within 30  min  (Table III).  Although we were unable to detect 
S-CRP  using fluorescein isothiocyanate anti-CRP  alone, the sensitivity of the biotin- 
avidin system permitted visualization of S-CRP  and observation of capping. 
Exogenous  CRP Does Not Alter NK Response.  The addition of CRP  to effector-target 
cell mixtures did not enhance or inhibit effector function, regardless of whether CRP 
was added  alone or as CRP-CPS  complexes (Table  IV).  This was examined  with a 
variety of effector cell  concentrations and  with  both  high  and  low  NK  responders. 
Even  minimal  enhancement  or  inhibition  would  have  been  observed  under  the 
conditions tested. Because many mononuclear phagocytic cells bind CRP, experiments 
were performed in  which adherent  cells or carbonyl  iron-ingesting phagocytes were 308  C-REACTIVE PROTEIN IN THE  NATURAL KILLER RESPONSE 
removed, thereby ensuring that  optimal concentrations of CRP or CRP-CPS com- 
plexes would be available for binding to lymphocytes. Neither CRP nor complexed 
CRP affected 51Cr release.  Similar results were obtained when the effects of H-CRP 
were examined (Table V). 
K562  Target Cells are not Killed by Treatment with Anti-CRP and C.  Because S-CRP is 
present  on NK effector cells,  we wondered whether CRP or its ligand might also be 
present on target cells, providing a mechanism for effector-target interactions. To test 
this,  K562 target cells  were preincubated  alone or in  the presence of CRP or CRP- 
CPS complexes, washed,  incubated  with  anti-CRP  and  C,  and  assessed  for loss  of 
viability by trypan blue exclusion.  No loss of K562 cell  viability was detected after 
incubation  with  anti-CRP  and  C,  regardless  of preincuhation  with  CRP  or CRP- 
CPS complexes (Table VI). In every case, the viability of groups treated with antibody 
alone was the same as that of groups treated with both antibody and complement. 
Discussion 
Treatment of human PBL with anti-CRP and C  removes functional NK activity 
to K562 target cells.  Similar treatment with anti-IgG or F(ab')2 anti-CRP antibodies 
and C does not inactivate the population of cells responsible for this killing.  Removal 
of phagocytic cells  and OKT3  ÷ T  cells  from an  LGL population does not  alter the 
removal of NK activity by antibody and C, suggesting that CRP or an antigenically 
related  molecule is  present  on the  NK effector cell  and  that  treatment  with whole 
antibody and C  removes this activity by C-mediated lysis of the effector cell popula- 
tion.  Although treatment  of NK effectors with  anti-CRP and C  removes nearly all 
functional NK activity, it  does not detectably decrease the number of ceils  present, 
perhaps  reflecting that  NK effectors  represent  <5°70 of the  PBL  (5).  These  results 
suggest that CRP may be a selective marker for some human NK effector cells. 
Although it has been reported (4) that CRP was detected on the surface of ~3% of 
PBL  only  after  a  preincubation  with  exogenous  CRP  in  the  presence  of  CPS, 
experiments  with  anti-CRP  and  C  in  which  functional  NK  activity was  depleted 
prompted us  to search  further  for S-CRP.  When sensitive  biotin-avidin or double- 
antibody techniques were used  for the detection of S-CRP, a  similar  percentage of 
cells  that  bind S-CRP was detected.  It is possibie that complexed CRP binds to S- 
CRP and  amplifies the amount of fluorescein isothiocyanate-conjugated anti-CRP. 
Alternatively, CRP-CPS complexes might bind to a  different  cell surface molecule. 
Additional studies of S-CRP are described elsewhere. 2 
Anti-CRP depleted NK effector function in the presence of C; however, the role of 
S-CRP in the NK response is not clear.  Early experiments in which an intermediate 
(1:8)  dilution of anti-CRP in  the absence of C  was used  resulted  in  variable loss of 
NK function, but  this loss was consistently seen  when larger amounts of anti-CRP 
were used. This suggested that either anti-CRP biocked a  molecuIe required  for an 
effector-target cell interaction or anti-CRP facilitated capping of a molecule required 
for an effective NK interaction. Capping studies indicate that removal of CRP could 
be responsible for loss of functional NK activity in the presence of high concentrations 
of anti-CRP alone. This supports the concept that removal of CRP or a molecule that 
co-caps directly with S-CRP affects the NK response. 
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This suggests that  CRP is involved in  the NK response.  Although  we know that 
involvement is at the level of the effector cell, the mechanism of action of CRP in the 
NK response  is not  yet  clear.  We  initially  thought  that  CRP-CPS  or CRP-ligand 
complexes could  serve as a  recognition  mechanism by bridging effector and  target 
cells in the NK response.  However, inasmuch as anti-CRP  plus C  did not  facilitate 
lysis of K562 and the inclusion of CRP or CRP-CPS complexes during the effector- 
target ceil interaction did not abrogate or enhance the NK activity observed, it seems 
unlikely that CRP is involved in bridging between effectors and targets. Studies are 
in progress to determine whether modulation of CRP is involved in the delivery of an 
internal signal to the NK effector cell. 
Although CRP or an antigenically similar molecule is present on a large percentage 
of the NK cells responsible for killing K562 target cells, when high numbers ofeffector 
cells  were  examined,  some  killing  activity  remained.  This  residual  activity  could 
represent  (a) effector cells that do not express S-CRP;  (b)  effector cells that express 
such a  low density of S-CRP that lysis with anti-CRP and C  is not effective; or (c) 
limited quantities of the antibody specifically reactive with S-CRP. The heterogeneous 
nature  of NK effector cells  (23)  make these  possibilities  likely.  MOLT-4 cells  and 
measles-infected  HEp-2  are  being  used  as  target  cells  to  determine  whether  the 
presence of S-CRP is limited to those NK effector cells that kill K562 targets. 
NK cells have been characterized primarily by functional activity. Abo et al.  (24, 
25)  and Lohmeyer et al. (26)  have isolated monoclonal antibodies that detect human 
NK cells; the former group termed the antigen reactivity with their antibody "HNK- 
1." HNK-1 was detected on 15 ___ 7% of PBL, and these were associated with both NK 
activity and  antibody-dependent  cell-mediated cytotoxicity  (24).  However, HNK-1 
expression did  not  correlate with  NK activity in  cord  blood of newborns or in  the 
blood of elderly individuals  (25).  Additionally,  the percent  of HNK-l-positive cells 
was much larger than the  1-5% of mononuclear cells considered to be responsible for 
NK  activity  (27,  28).  The  two  monoclonal  antibodies  of  Lohmeyer  et  al.  (26) 
recognized  antigens  present  on  suppressor  and  cytotoxic  effector cells  or  those  on 
monocytes, neutrophils,  and  null  cells as well as NK cells.  Thus,  a  single antibody 
that recognizes only NK cells has not yet been described. The monoclonal antibodies 
to human  NK cells appear to detect  a  determinant  different  from S-CRP,  because 
they react with more PBL than does anti-CRP and do not deplete NK function in the 
absence of C  (24). 
The IgG anti-CRP used in our studies was generated with highly purified CRP as 
antigen  (13)  and was derived from an antibody preparation that had been shown to 
be free of all known contaminants (4). Activity was retained upon further purification 
by CRP-affinity column chromatography, emphasizing that the reactivity observed 
was due to an interaction with an antigen or antigens present on purified CRP. To 
further establish that  removal of functional  NK activity was due to reactivity with 
CRP, we have prepared several monoclonal antibodies directed against CRP. Seven 
of nine of these monoclonals detected percentages of PBL displaying S-CRP similar 
to  those  detected  with  the  antibody  used  in  the  experiments  described  herein. 2 
Kearney et  al.  (29)  and  Kilpatrick et  al.  (30)  have described  an  IgM  monoclonal 
antibody to CRP that did not detect lymphocytes or neutrophils but did react with 
all peripheral blood monocytes. This monoclonal anti-CRP antibody did not bind to 
lymphocytes detected  by  HNK-1.  Perhaps  this  monoclonal  anti-HNK-1  antibody 310  C-REACTIVE PROTEIN  IN THE  NATURAL KILLER RESPONSE 
recognizes a  determinant  of CRP  that  is not  available for binding on  NK  cells or 
binds  to  a  subpopulation  of NK  that  does not  bear CRP.  Studies are currently in 
progress to determine whether  HNK-1  is present on  the cells that  interact with our 
polyvalent  anti-CRP  and  to  determine  the  effects  of  our  monoclonal  anti-CRP 
antibodies on NK activity. 
Summary 
Functional  NK  activity can  be removed  from  human  PBL  and  from  phagocyte- 
and  T  cell-depleted LGL  preparations  by  treatment  with  antisera  specific  for  C- 
reactive  protein  (CRP)  in  the  presence  of complement  (C).  Pretreatment  of  NK 
effector cells with high concentrations of anti-CRP  in the absence of C  also depletes 
functional  activity.  These  results  indicate  that  CRP  or  an  antigenically  similar 
molecule is present on a  population of NK effector cells. Fluorescent antibody studies 
in which  biotin-avidin amplification was used confirm the presence of surface CRP 
(S-CRP) on a small percentage of nonphagocytic peripheral blood mononuclear cells. 
S-CRP readily caps off, which suggests that  removal by capping obviates killing by 
this cell population.  This  indicates that  S-CRP  or a  molecule that  co-caps with  S- 
CRP  may be required for successful effector-target cell interaction. The addition of 
exogenous  CRP  or CRP-CPS  complexes, however,  does  not  alter NK  responses.  A 
subpopulation  of  lymphoid  cells  responsible  for  functional  NK  activity  therefore 
appears to bear surface CRP. 
Received  for publication 8 April 1982 and in revised  form 14 September 1982. 
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